Table 1. Randomized, controlled CT screening studies.
| Study | Screen modality: no. participants | Noncalcified nodules (baseline) | Total no. of cancers detected | Surgical stage I | Deaths from lung cancer | Mortality reduction |
|---|---|---|---|---|---|---|
| DANTE [22] | CT: 1276 | 27.5% | 58 (4.5%) | 71% | 11 | NR |
| No screen: 1196 | nr | 25 (2.1%) | 52% | 10 | ||
| Depiscan [21] | CT: 336 | 45.2% | 8 (2.4%) | 37.5% | nr | NR |
| CXR: 285 | 7.4% | 1 (0.4%) | 100% | nr | ||
| DLSCT [23] | CT: 2052 | 27.3% | 69 (3.4%) | 68% | 15 | None |
| No screen: 2052 | nr | 24 (1.2%) | 21 | 11 | ||
| ITALUNG [20] | CT: 1406 | 30%* | 21 (1.5%) | 47.6% | nr | NR |
| No screen: 1593 | nr | nr | nr | nr | ||
| NELSON [19] | CT: 7557 | 50.5% | 70 (0.9%) | 63.9% | nr | NR |
| No screen: nr | nr | nr | nr | nr | ||
| NLST [16] | CT: 26722 | 27.3** | 1060 | 50% | 356 | 20.0% |
| CXR: 26732 | 9.2 | 941 | 30.7% | 443 |
NR: not reported
* reported as positive if a nodule ≥ 5 mm was detected
** reported as positive if a nodule ≥ 4 mm was detected